These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11447097)

  • 41. Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
    Ryan MJ; Gibson J; Simmons P; Stanek E
    Am J Cardiol; 2003 Jun; 91(12):1427-31. PubMed ID: 12804728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The surprising AIM-HIGH results are not surprising when viewed through a particle lens.
    Otvos JD
    J Clin Lipidol; 2011; 5(5):368-70. PubMed ID: 21981836
    [No Abstract]   [Full Text] [Related]  

  • 45. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trial puts niacin--and cholesterol dogma--in the line of fire.
    Dolgin E
    Nat Med; 2011 Jul; 17(7):756. PubMed ID: 21738133
    [No Abstract]   [Full Text] [Related]  

  • 48. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin.
    Heart Advis; 2010 Nov; 13(11):5. PubMed ID: 22834056
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease.
    Mark L; Katona A; Marki-Zay J
    Am J Cardiol; 2002 Jan; 89(1):111. PubMed ID: 11779542
    [No Abstract]   [Full Text] [Related]  

  • 52. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
    Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
    Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Commentary: A new approach to atherogenic dyslipidemia.
    Reasner CA
    Postgrad Med; 2005 Apr; 117(4):13-6. PubMed ID: 15842128
    [No Abstract]   [Full Text] [Related]  

  • 54. Estrogen-receptor polymorphism and hormone-replacement therapy.
    Garrido JA
    N Engl J Med; 2002 Sep; 347(10):762-3; author reply 762-3. PubMed ID: 12213951
    [No Abstract]   [Full Text] [Related]  

  • 55. Niacin as antidyslipidemic drug.
    Julius U
    Can J Physiol Pharmacol; 2015 Dec; 93(12):1043-54. PubMed ID: 26370906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA
    J Am Coll Cardiol; 2009 Nov; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract]   [Full Text] [Related]  

  • 57. Niacin is still beneficial. Implications from an updated meta-regression analysis.
    Siniawski D; Santos-Gallego CG; Badimon JJ; Masson WM
    Acta Cardiol; 2016 Aug; 71(4):463-72. PubMed ID: 27594363
    [No Abstract]   [Full Text] [Related]  

  • 58. What restricts the clinical use of nicotinic acid?
    Kei A; Liberopoulos EN; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):521-30. PubMed ID: 21314634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A case report of a diabetic woman with very low HDL cholesterol.
    Chaychi L; Kinlaw WB; Asztalos BF; Schaefer EJ
    J Clin Lipidol; 2010; 4(2):133-5. PubMed ID: 21122641
    [No Abstract]   [Full Text] [Related]  

  • 60. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.